Key terms
About TEVA
Teva Pharmaceutical Industries Ltd. engages in the development, production, and sale of medicines. It operates through the following geographical segments: North America, Europe, and International Markets. The company was founded in 1901 and is headquartered in Tel Aviv, Israel.
Sector
Industry
Employees
Founded
Website
Key stock statistics
1-day range
52-week range
Market cap
P/E ratio
Next earnings date
Dividend yield
Ex-dividend date
Dividend pay date
Key terms
Ad Feedback
Smart score
Latest TEVA news
Mar 08
9:40am ET
GE upgraded, Vail Resorts downgraded: Wall Street’s top analyst calls
Mar 08
7:10am ET
Teva upgraded to Neutral from Underweight at JPMorgan
Mar 04
9:27am ET
UBS confident in Teva’s continued growth trajectory
Feb 26
7:55am ET
Piper Sandler Sticks to Its Buy Rating for Teva Pharmaceutical (TEVA)
Feb 26
7:12am ET
Teva, Jiangsu Nhwa Pharmaceutical enter partnership
Feb 25
6:23am ET
Alvotech, Teva announce U.S. approval of SIMLANDI injection
Feb 20
10:35am ET
Teva put volume heavy and directionally bearish
Feb 20
9:09am ET
Teva presents data confirming target engagement o TEV-‘574 at ECCO meeting
Feb 13
1:00am ET
Teva Pharmaceutical Industries Limited Is Worried About This – Should You Be Worried Too?
Feb 12
9:47am ET
Teva rises 5.2%
Feb 12
5:04am ET
Teva upgraded to Overweight from Neutral at Piper Sandler
Feb 12
5:02am ET
Analysts Offer Insights on Healthcare Companies: India Globalization Capital (IGC), Tango Therapeutics (TNGX) and Teva Pharmaceutical (TEVA)
Feb 05
7:30am ET
Analysts Offer Insights on Healthcare Companies: Siemens Healthineers AG (OtherSEMHF), Teva Pharmaceutical (TEVA) and ACADIA Pharmaceuticals (ACAD)
Feb 05
5:46am ET
Teva price target raised to $17 from $15 at Barclays
Feb 05
2:56am ET
Barclays Sticks to Its Buy Rating for Teva Pharmaceutical (TEVA)
Feb 05
12:05am ET
Goldman Sachs Sticks to Its Hold Rating for Teva Pharmaceutical (TEVA)
Feb 01
7:39am ET
Teva price target raised to $16 from $15 at UBS
Feb 01
4:25am ET
UBS Remains a Buy on Teva Pharmaceutical (TEVA)
Jan 31
8:58am ET
Teva expects ‘stabilization’ of generics business in North America in 2024
Jan 31
8:29am ET
Teva (NYSE:TEVA) Delivers Q4 Beat; To Divest API Unit
Jan 31
8:27am ET
Teva expects 2H24 revenue ‘slightly higher’ than 1H24
Jan 31
8:12am ET
Teva expects Austedo to achieve $2.5B in sales by 2027
Jan 31
7:15am ET
Teva sees FY24 EPS $2.20-$2.50, consensus $2.42
Jan 31
7:11am ET
Teva reports Q4 EPS $1.00, consensus 77c
Jan 31
7:05am ET
Options Volatility and Implied Earnings Moves Today, January 31, 2024
Jan 31
6:02am ET
Teva plans to divest its active-pharmaceutical ingredient business
Jan 29
5:07am ET
Barclays Remains a Buy on Teva Pharmaceutical (TEVA)
Jan 25
6:19am ET
Teva price target raised to $11 from $9 at JPMorgan
Jan 24
6:14am ET
Teva price target raised to $15 from $13 at UBS
Jan 23
9:51am ET
Nvidia initiated, Tractor Supply downgraded: Wall Street’s top analyst calls
Jan 23
9:51am ET
Nvidia initiated, Tractor Supply downgraded: Wall Street’s top analyst calls
No recent news articles are available for TEVA
No recent press releases are available for TEVA
TEVA Financials
Key terms
Ad Feedback
TEVA Forecasts
analyst rating
- buy
- hold
- sell
1-year stock price forecast
TEVA Competitors
$ Market cap
P/E ratio
$ Price
1d change
52-week range